RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
2.110
+0.180 (9.33%)
At close: Sep 1, 2026, 4:00 PM EDT
2.130
+0.020 (0.95%)
After-hours: Sep 1, 2026, 7:09 PM EDT
RenovoRx Revenue
RenovoRx had revenue of $909.00K in the quarter ending June 30, 2026, with 115.40% growth. This brings the company's revenue in the last twelve months to $1.98M, up 198.49% year-over-year. In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth.
Revenue (ttm)
$1.98M
Revenue Growth
+198.49%
P/S Ratio
46.36
Revenue / Employee
$116,235
Employees
17
Market Cap
95.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
RNXT News
- 4 days ago - RenovoRx price target raised to $14.50 from $14 at Ascendiant - TheFly
- 7 days ago - RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial - TheFly
- 7 days ago - RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 11 days ago - RenovoRx regains compliance with Nasdaq - TheFly
- 11 days ago - RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 12 days ago - RenovoRx receives notice of allowance for new RenovoCath U.S. patent - TheFly
- 12 days ago - RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - GlobeNewsWire
- 15 days ago - RenovoRx reports Q2 EPS (5c), consensus (8c) - TheFly